[{"id":"38ae3e19-8dad-4b01-a570-b25b5bcb525a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06919666","created_at":"2025-06-21T13:16:45.845Z","updated_at":"2025-06-21T13:16:45.845Z","phase":"Phase 1/2","brief_title":"NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06919666","lead_sponsor":"University of Colorado, Denver","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • NT219"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 02/01/2030","primary_completion_date":" 02/01/2030","study_txt":" Completion: 02/01/2031","study_completion_date":" 02/01/2031","last_update_posted":"2025-06-18"},{"id":"06c95d25-232d-4edf-bad2-62ebafe8d024","acronym":"","url":"https://clinicaltrials.gov/study/NCT04474470","created_at":"2021-01-18T21:29:42.332Z","updated_at":"2024-07-02T16:35:04.621Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer","source_id_and_acronym":"NCT04474470","lead_sponsor":"TyrNovo Ltd.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • RAS wild-type + BRAF wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • RAS wild-type + BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • NT219"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/03/2020","start_date":" 09/03/2020","primary_txt":" Primary completion: 05/08/2024","primary_completion_date":" 05/08/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-05-09"}]